UNC Study: Incretin Drugs Like Semaglutide Linked to Significant Muscle Loss in Weight Reduction

Researchers at the University of North Carolina School of Medicine have uncovered compelling evidence that popular weight loss drugs, known as incretin-based medications like semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound), lead to notable muscle loss alongside fat reduction. This finding, detailed in a comprehensive systematic review published in the Annals of Internal Medicine, highlights a critical aspect of these therapies that warrants closer attention from healthcare providers and patients alike.

The study, led by John A. Batsis, MD, an associate professor in the Department of Medicine and Nutrition at UNC, analyzed data from 36 randomized controlled trials involving thousands of participants. These trials examined body composition changes using precise methods such as dual-energy X-ray absorptiometry (DXA), bioelectrical impedance analysis (BIA), computed tomography (CT), and magnetic resonance imaging (MRI). The results showed that, on average, about 35% of the total weight lost with these medications came from muscle-related tissues, often surpassing established benchmarks for safe weight loss.

Understanding Incretin-Based Medications and Their Rise

Incretin-based medications mimic hormones produced in the gut that regulate blood sugar and appetite. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, slow gastric emptying, reduce hunger signals to the brain, and improve insulin sensitivity. Dual agonists like tirzepatide also target glucose-dependent insulinotropic polypeptide (GIP) receptors, amplifying these effects. Since their approval for obesity treatment, prescriptions have skyrocketed, with millions using them for substantial weight loss—often 15-20% of body weight over a year.

However, rapid weight reduction, regardless of method, typically involves some loss of lean mass. What sets incretin therapies apart, according to the UNC analysis, is the higher proportion relative to other approaches like diet and exercise alone.

Key Findings from the UNC Systematic Review

The UNC team's review spanned trials from 2003 to early 2026, focusing on adults with obesity or type 2 diabetes. Key metrics included fat-free mass (FFM), appendicular lean mass, and skeletal muscle area. In incretin groups:

• Median total weight loss was substantial, accompanied by significant fat and visceral fat reductions.
• 34.9% (interquartile range: 19%-48.2%) of weight loss was from muscle indices; 68% of studies exceeded the 25% benchmark for DXA/BIA.
• For CT/MRI studies, 35.8% (29.8%-50.4%), all surpassing the 15% threshold.
• Semaglutide and tirzepatide subgroups showed even higher muscle contributions.

In contrast, lifestyle or placebo arms had minimal weight loss (-2.4%), with 50% exceeding benchmarks—indicating muscle loss is inherent to caloric deficit but amplified by these drugs' potency. No trials measured physical function like strength or gait speed, a notable gap highlighted by Batsis.

UNC Health News Release details the plenary presentation at the American College of Physicians meeting.

Why Muscle Loss Matters: Health Risks and Sarcopenia Concerns

Muscle, or skeletal mass, is vital for metabolism, mobility, bone health, and insulin sensitivity. Losing it disproportionately—termed sarcopenic obesity—raises risks of frailty, falls (especially in those over 65), metabolic slowdown, and weight regain post-treatment. UNC notes few studies include older adults, where baseline muscle is already declining 1-2% yearly after age 50.

Real-world data echoes this: up to 40% of GLP-1 weight loss can be lean mass in some users, per prior reviews. This underscores the need for body composition scans beyond scale weight.

Comparisons to Diet, Exercise, and Bariatric Surgery

The UNC review positions incretin drugs against non-drug interventions. Lifestyle changes (calorie restriction + exercise) preserve more muscle via resistance training. Bariatric surgery studies show ~25-30% muscle loss of total weight, similar but with surgical risks.

• Placebo/lifestyle: Lower absolute loss but proportional when weight drops.
• Incretins: Greater total loss, higher muscle percentage.

Batsis emphasizes: "Team-based approaches with lifestyle therapies alongside medications are critical."

Photo by Bernd 📷 Dittrich on Unsplash

Expert Perspectives from UNC and Beyond

"These findings suggest the magnitude of muscle loss relative to total weight loss warrants closer attention," Batsis stated. He advocates shared decision-making, starting low doses, and adjunct therapies. No studies assessed function, urging future trials on mobility and quality of life.

Harvard's Vishwa Deep Dixit notes GLP-1s may improve muscle quality (less fat infiltration), but quantity matters. Mayo Clinic experts recommend monitoring via DEXA scans.

Healio coverage quotes Batsis on individualizing care.

Proven Strategies to Mitigate Muscle Loss

University-led research offers actionable solutions:

• Resistance Training: 3x/week (e.g., weights, bodyweight) preserves 80-90% lean mass, per UAlberta and STEP-HFpEF trials.
• High-Protein Diet: 1.2-1.6g/kg body weight daily (e.g., 100-150g for 80kg person) from lean meats, dairy, plants. Mass General studies show synergy with GLP-1s.
• Ketone Supplements: UAlberta trial: Ester protects muscle during caloric deficit.
• Monitoring: DEXA or BIA every 3-6 months.

Combined, these cut muscle loss to <20%, maintaining strength.

Ongoing University Research on GLP-1 Muscle Dynamics

UNC's work builds on global efforts. UAlberta tests ketones; Vanderbilt examines dual agonists. Clinical trials like SLIM-AP (UNC-affiliated) integrate exercise. Stanford explores myostatin inhibitors to boost muscle during therapy.

Higher ed plays key: Med schools train providers on composition-focused obesity care.

Implications for Clinical Practice and Policy

Prescribers should screen for sarcopenia risk, counsel on exercise/protein, and refer to dietitians. FDA labels may evolve; insurers could cover DEXA. For universities, this spurs interdisciplinary research in aging, nutrition, endocrinology.

Annals of Internal Medicine study calls for standardized outcomes in trials.

Future Outlook: Balancing Benefits and Risks

Incretins revolutionize obesity treatment, slashing cardiometabolic risks. With mitigations, muscle concerns are manageable. UNC's Batsis envisions personalized regimens: drugs + lifestyle for optimal body comp. Watch for next-gen agonists preserving muscle better.

Patients: Consult providers; prioritize strength. Researchers: Fill gaps in geriatric data, function measures.

Photo by Vitaly Gariev on Unsplash

This UNC-led insight reframes weight loss success beyond pounds, emphasizing quality. As universities drive evidence, healthier outcomes await.